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S U M M A R Y
We report the ﬁrst occurrence of New Delhi metallo-b-lactamase 5 (NDM-5) in carbapenem-resistant
Escherichia coli isolated from blood cultures of three leukemia patients in northern China. These patients
had at some time been hospitalized in the hematology department of the same hospital. All isolates were
ST167 with identical pulsed-ﬁeld gel electrophoresis patterns, suggesting a likely hospital transmission.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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New Delhi metallo-b-lactamase 1 (NDM-1) has received
worldwide attention since it was ﬁrst reported in Klebsiella
pneumoniae recovered from a Swedish patient previously hospi-
talized in India. This is because of its severe resistance to almost all
types of antibiotic, although NDM-1 has also captured worldwide
attention because of its frequent association with additional
resistance genes, presence in many common pathogens, and
nosocomial spread.1 As well as NDM-1, the ﬁrst NDM-5-producing
isolate was recovered from a patient with a recent history of
hospitalization in India. As reported previously, NDM-5 differs
from existing enzymes due to substitutions at positions 88
(Val!Leu) and 154 (Met!Leu), and reduces the susceptibility of
Escherichia coli TOP10 transformants to extended-spectrum
cephalosporins and carbapenems when expressed under its native
promoter.2 The detection of NDM-5 in three clinical isolates of
carbapenem-resistant E. coli in northern China is reported herein.
2. Case report
The three NDM-positive E. coli isolates designated E1–E3 were
recovered from blood cultures of three different hospitalized* Corresponding author.
E-mail address: 13309889399@189.cn (D.-y. Meng).
http://dx.doi.org/10.1016/j.ijid.2015.10.006
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).inpatients admitted to the Hematology Department of the General
Hospital of Shenyang Military Command, Shenyang, China in
2014. The ﬁrst isolate was recovered from a 56-year-old man who
was diagnosed with acute leukemia and hospitalized from March
20 to April 24. The second was obtained from a 22-year-old male
patient with B-lymphocytic leukemia who was hospitalized from
April 2 to May 28. The third isolate was collected from a 63-year-
old man with acute non-lymphocytic leukemia who was hospital-
ized on June 9 and died after 89 days of hospitalization. All three
patients had undergone chemotherapy, blood cell transfusions,
and prophylactic antibiotic therapy (imipenem and vancomycin).
The identiﬁcation of the three isolates was conducted using the
Vitek-2 AMS system (bioMe´rieux, France). The minimum inhibi-
tory concentrations (MICs) of selected antimicrobials were
determined by broth microdilution method in accordance with
the Clinical and Laboratory Standards Institute (CLSI) guidelines.
All strains were resistant to the antibiotics, except one isolate that
was susceptible to gentamicin. The resistance patterns are
illustrated in Table 1.
All three isolates were positive for the modiﬁed Hodge test and
EDTA–imipenem synergy test (Oxoid, UK), performed as recom-
mended by the CLSI. The presence of blaNDM (5
0-GTCTGGCAGCA-
CACTTCCTA-30 and 50-TAGTGCTCAGTGTCGGCATC-30), blaKPC (50-
TGTCACTGTATCGCCGTC-30 and 50-CTCAGTGCTCTACAGAAAACC
-30), and membrane protein genes (ompC and ompF)3 was screened
by PCR. The isolates were positive for blaNDM, but negative forciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Minimum inhibitory concentrations (mg/ml) for Escherichia coli isolates
Antibiotics
CXM CRO CFP CIP GEN IPM MEM TZP
CLSI resistance
breakpoint
32 4 64 8 16 4 4 128/4
E1 512 512 512 512 128 16 64 512
E2 512 512 512 512 128 16 32 512
E3 512 512 512 512 1 16 32 512
CXM, cefuroxime; CRO, ceftriaxone; CFP, cefoperazone; CIP, ciproﬂoxacin; GEN,
gentamicin; IPM, imipenem; MEM, meropenem; TZP, piperacillin/tazobactam;
CLSI, Clinical and Laboratory Standards Institute.
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identiﬁed them as blaNDM-5-carrying.
Since the three patients had been hospitalized in the same
department, and two of them had been hospitalized at the same
time, multilocus sequence typing (MLST) and pulsed-ﬁeld gel
electrophoresis (PFGE) were applied for analysis and molecular
typing. The sequence type of all isolates was ST167, which is an
internationally disseminated clone belonging to the ST10 complex.
Their PFGE patterns were identical, with the same numbers of
bands, and the corresponding bands were of the same apparent
size.
3. Discussion
The three NDM-5-producing isolates were resistant to carba-
penems and cephalosporins because the NDM enzyme hydrolyzes
b-lactams. However, the resistance pattern to gentamicin was
totally different. The major factor conferring aminoglycoside
resistance is the aminoglycoside-modifying enzymes, and the
intracellular location of these enzymes may have a role in
determining the level of resistance.4 Aminoglycoside-modifying
enzyme genes may derive from genes encoding enzymes involved
in normal cellular metabolism that always remain silent, and
selective pressure of aminoglycoside usage may cause mutations
and alter the expression of these enzymes. Hence, it is possible that
the three isolates exhibited different resistance patterns to
gentamicin.
These ST167 isolates with identical PFGE patterns were closely
related to each other, but there was no signiﬁcant evidence to
verify whether the patients were cross-infected as they had been
hospitalized in different wards and were treated by different
doctors. Prophylactic antibiotic usage, chemotherapy, blood cell
transfusions, and invasive procedures could all be involved in
nosocomial infection. As reported, the NDM genes are locatedexclusively on plasmids and most plasmids readily undergo
horizontal transfer, which implies an alarming potential for
spread. Other studies have also found invasive procedures with
bacterial-contaminated facilities to be associated with the
transmission of NDM-producing E. coli. The selective pressure of
the use of carbapenem antibiotics as initial prophylaxis has made
carbapenem-resistant isolates dominant. All of the patients
became infected with this NDM-5-producing E. coli during therapy.
Finally, one patient died, one patient ceased treatment, and one
was transferred to another hospital.
To date, NDM-5-producing Enterobacteriaceae have been
reported in India (ST648), Algeria (ST2569), Japan (ST540), Spain
(ST448), the UK (ST648),2 USA (ST167), Australia (ST648), and West
China (ST167)5 since they were ﬁrst reported. To our knowledge,
this is the ﬁrst report of NDM-5-producing E. coli isolated from
cancer patients in China. Before this, a case of ST167 NDM-5-
producing E. coli in a 75-year-old male patient with an acute
exacerbation of chronic obstructive pulmonary disease was
reported from a hospital in West China in 2014.5 Although all
four patients reported in China had no history of travel abroad, it
remains unclear whether the ST167 NDM-5-positive isolates
originated in China or not, and this requires further study. Some
imported medical apparatus and instruments may have been the
source of the infection. Cancer sufferers comprise a large
proportion of hospitalized patients, and the use of chemother-
apeutics and prophylactic antibiotics increases their chance of
becoming infected.
This report will remind clinical doctors of the occurrence of
‘superbugs’. We cannot avoid the use of antibiotics or the
inevitable selective pressure resulting in the emergence of
multidrug-resistant isolates, but we can control this through
appropriate antibiotic usage and periodical monitoring. Further-
more, regular nosocomial infection control is absolutely necessary.
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